Ribociclib also demonstrated synergistic activity in PI3K inhibitor-resistant, PIK3CA-mutant breast cancer cell lines, with the PI3K inhibitors pictilisib (GDC-0941) or alpelisib. Here, PIK3CA is linked to breast carcinoma.